Cartesian Therapeutics, Inc. (RNAC) shares soared 26.9% in the last trading session to close at $22.82. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 33.7% gain over the past four weeks. The recent surge in the stock price is driven by positive investor expectations regarding the company's pipeline of novel mRNA cell therapy for autoimmune diseases. Cartesian is currently assessing its lead candidate, Descartes-08, in two separ ...